Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Abstract Background Cardiovascular toxicity is a notorious complication of doxorubicin (DXR) therapy for diffuse large B-cell lymphoma (DLBCL). Although surveillance of well-known biological markers for cardiovascular disease (CVD) as NTproBNP and Troponins may be helpful, there are no established m...

Full description

Bibliographic Details
Main Authors: Charlott Mörth, Amal Abu Sabaa, Eva Freyhult, Christina Christersson, Jamileh Hashemi, Nashmil Hashemi, Masood Kamali-Moghaddam, Daniel Molin, Martin Höglund, Anna Eriksson, Gunilla Enblad
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Cardio-Oncology
Subjects:
Proteomics
Lymphoma
Cardiac toxicity
Doxorubicin
Online Access:https://doi.org/10.1186/s40959-021-00092-0

Internet

https://doi.org/10.1186/s40959-021-00092-0

Similar Items